Sebastian Gensior

The final week of January 2026 delivered the largest licensing deal of the year so far, a collapsed mega-merger, and continued momentum in venture fundraising and IPO activity. AstraZeneca committed up to $18.5 billion for obesity assets from China, while Merck walked away from a potential $30 billion acquisition.

2025-2026 Market Overview: Record Volume Reshapes the Landscape Before diving into the technical intricacies of liens, it is worth pausing to appreciate the sheer scale of the market these security interests now protect. The pharmaceutical royalty financing market reached a historic $10 billion in announced transaction value in 2025, fundamentally

SLR Investment Corp. (NASDAQ: SLRC) is a New York-based business development company externally managed by SLR Capital Partners, a specialty finance platform with approximately $12 billion in assets under management. Founded in 2007 and publicly traded since its February 2010 IPO, SLRC operates as a closed-end investment company regulated under

Executive Summary Mendra, Inc. is a newly launched San Francisco-based biopharmaceutical company targeting high-unmet-need rare diseases. In January 2026, the company announced an oversubscribed $82 million Series A financing co-led by OrbiMed, 8VC, and 5AM Ventures, with participation from Lux Capital and Wing VC. The startup's mission is

The Gulf Cooperation Council (GCC) pharmaceutical industry is undergoing significant structural changes as sovereign wealth funds deploy capital and local manufacturers expand biosimilar portfolios and manufacturing capacity. The combined GCC market reached approximately $23.7 billion in 2024, with projections targeting $49 billion by 2033 at a 7.6% CAGR.

The Pension Fund Challenge—And Why Royalties Address It Defined benefit pension plans face a structural dilemma: actuarial assumptions of 6-7% annual returns must be met against a backdrop of compressed fixed income yields and elevated equity valuations. Traditional 60/40 portfolios no longer generate sufficient risk-adjusted returns to meet

What Are Indication-Specific Royalties? Indication-specific royalties are royalty financing or licensing arrangements where payments are tied only to sales of a product in a particular indication (i.e. a specific therapeutic use or medical condition). In other words, if a drug or device is approved for multiple uses, an indication-specific

The third week of January, recorded over $10 billion in confirmed and potential transaction value across 30+ biotech, pharmaceutical, and healthcare deals globally. GSK's $2.2 billion acquisition of RAPT Therapeutics headlined M&A activity, while Shionogi's $2.125 billion investment to double its ViiV

The pharmaceutical royalty market has deployed over $29 billion since 2020 into patent-protected assets—yet systematically ignores a parallel universe of monetizable cash flows worth multiples of that amount. Established consumer health brands, branded generics, mature biologics facing biosimilar competition, and the biosimilar portfolios themselves generate tens of billions annually

BCM Europe AG occupies an unusual position in the pharmaceutical financing landscape. The Zug-based investment company has quietly assembled control over a NASDAQ-listed holding company, acquired a clinical-stage immuno-oncology platform, and is now attempting to execute an $845 million licensing transaction that would pay half its upfront consideration in digital